A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Clinical trial NCT02421939 · COMPLETED

Trial details

NCT number: NCT02421939
Sponsor: Astellas Pharma Global Development, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Leukemia, Acute Myeloid (AML)

Start date: 2015-10-20
Primary completion: 2018-09-17
Enrollment: 371

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.